Transdermal testosterone failed to increase libido in female cancer survivors . . .

Article

S

. . . according to the results of a phase III, randomized, placebo-controlled, crossover trial.

Researchers studied 150 postmenopausal cancer survivors with no evidence of current disease who reported a decrease in sexual desire and had a sexual partner. An important distinction is that the women were estrogen replete. Unlike in other recent placebo-controlled trials reporting a benefit of transdermal testosterone on libido, the women in this trial were receiving no other hormone therapy of any kind. The women received either 2% testosterone in Vanicream for a testosterone dose of 10 mg daily or placebo cream for 4 weeks and were then crossed over to the opposite treatment for an additional 4 weeks.

Women receiving the active testosterone cream had higher serum levels of bioavailable testosterone than the women receiving the placebo, but this did not translate into a change in libido; the average intrapatient libido change from baseline to weeks 4 and 8 was similar in both groups.

Barton DL, Wender DB, Sloan JA, et al. Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group Protocol N02C3. J Natl Cancer Inst. 2007;99:672-679.

Recent Videos
COVID-19 Therapy Roundtable: Defining the virus today and treatment options | Image Credit: © Production Perig - © Production Perig - stock.adobe.com.
How fezolinetant advances non-hormonal treatment of hot flashes | Image Credit: medschool.cuanschutz.edu
Contraceptive access challenges for college students in contraception deserts | Image Credit: linkedin.com.
Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.